<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3628">
  <stage>Registered</stage>
  <submitdate>28/08/2012</submitdate>
  <approvaldate>28/08/2012</approvaldate>
  <nctid>NCT01675596</nctid>
  <trial_identification>
    <studytitle>The SOLACE-AU Clinical Trial</studytitle>
    <scientifictitle>A Multicentre, Non-Randomised Controlled Study of the Safety, Performance, Quality of Life and Cost Effectiveness Outcomes of the Edwards SAPIEN XT Transcatheter Heart Valve in an Australian Population</scientifictitle>
    <utrn />
    <trialacronym>SOLACE-AU</trialacronym>
    <secondaryid>2011-14</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Severe, Symptomatic Aortic Stenosis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - TAVR Implantation of the Transcatheter Aortic Valve Prosthesis

Experimental: Test - SAPIEN XT valve with the NovaFlex and NovaFlex+ delivery systems.


Treatment: devices: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Operable subjects

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>VARC-2 composite safety endpoint - The primary endpoint is a VARC-2 Composite. It comprises of
All cause mortality
Major stroke
Life-threatening (or disabling) bleeding
Acute kidney injury - Stage 3 (including renal replacement therapy)
Major vascular complications
Repeat procedure for valve-related dysfunction (surgical or interventional therapy)</outcome>
      <timepoint>30 days post index procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All cause mortality</outcome>
      <timepoint>6 months post index procedure</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All cause mortality</outcome>
      <timepoint>12 months post index procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt; 70 years

          -  STS Score &gt; 4

          -  Heart team agrees on eligibility including assessment that TAVR or AVR is appropriate</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Age &lt;70 years

          -  Evidence of an acute myocardial infarction = 30 days

          -  Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is
             non-calcified

          -  Stroke or transient ischemic attack (TIA) within 6 months of the procedure</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>198</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Macquarie Unversity Hospital - Macquarie Park</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>St Vincent's Hospital - MELBOURNE - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Royal Perth Hospital/Fiona Stanley Hospital - Perth</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2109 - Macquarie Park</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3065 - Melbourne</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Edwards Lifesciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Pacific Clinical Research Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of the study is to observe the safety, efficacy and cost effectiveness of the
      Edwards SAPIEN XT valve for the treatment of severe calcific degenerative aortic stenosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01675596</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Darren Walters, Prof.</name>
      <address>The Prince Charles Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>